6 month supply of semaglutide Sema Initial Program – Months (New Patients) – $99/month | CoraDoc™ A month's supply of the

Novo Nordisk maintains the highest strategic value in the GLP-1 Weight Loss Drug Market competitive landscape through first-mover advantage in dedicated obesity pharmacotherapy, manufacturing scale exceeding 24 billion API doses annually following the Catalent site acquisition, and a multi-indication strategy converting Wegovy into a broad metabolic disease platform

ALOX12 inactivation abolishes p53-mediated ferroptosis in lymphoma

Caution is warranted because animal findings do not reliably map onto what happens in people

Early results vary widely based on starting weight, adherence to the medication schedule, and lifestyle factors like diet and activity level

Additionally, patients with heart failure especially those with reduced ejection fraction should be monitored closely for increases in heart rate when starting GLP-1 therapies